+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Screening Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 180 Pages
  • February 2024
  • Region: Global
  • Expert Market Research
  • ID: 5941067

Global Lung Cancer Screening Market Outlook

The global lung cancer screening market size was valued at USD 2.5 billion in 2023, driven by increasing prevalence of lung cancer. The market size is anticipated to grow at a CAGR of 8.2% during the forecast period of 2024-2032 to achieve a value of USD 5.1 billion by 2032.

Lung Cancer Screening: Introduction

Lung cancer screening is a medical procedure used to detect lung cancer in its early stages, particularly among high-risk individuals, such as long-term smokers. The most common method is low-dose computed tomography (LDCT), a type of X-ray that provides detailed images of the lungs, enabling the detection of small nodules or abnormalities that may indicate early-stage lung cancer. Early detection through screening is crucial as it significantly improves treatment success rates and overall patient survival.

Key Trends in the Global Lung Cancer Screening Market

Increasing focus on personalized treatment plans based on genetic profiling of tumors, allowing for more targeted and effective therapies. Breakthroughs in immunotherapy are providing new hope, with treatments that help the immune system recognize and fight cancer cells more effectively.

Enhanced emphasis on early detection through advanced screening technologies like low-dose CT scans, aiming to diagnose lung cancer at more treatable stages. Growing trend towards using a combination of treatment methods, including surgery, radiation, chemotherapy, and targeted therapies, to improve patient outcomes.

Integration of digital tools and AI in diagnostics, treatment planning, and patient monitoring, aiming to optimize treatment paths and improve prognostic evaluations. Increased availability of support services focusing on the mental and emotional well-being of patients and their families, recognizing the importance of holistic care in cancer treatment.

Evolving regulatory policies and reimbursement models to support the adoption of innovative treatments and ensure patients have access to the latest and most effective therapies.

Global Lung Cancer Screening Market Segmentation

Market Breakup by Type

  • Low dose computed tomography (LDCT)
  • X-ray

Market Breakup by Age Group

  • 50 and older
  • Below 50

Market Breakup by End User

  • Hospitals
  • Diagnostic Centers
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Lung Cancer Screening Market Overview

In North America, the lung cancer market is highly advanced with a strong emphasis on early detection and cutting-edge treatment options. There is a significant focus on lung cancer screening programs, particularly using low dose computed tomography (LDCT), to catch the disease at a more treatable stage. The region also sees a high adoption rate of targeted therapies and immunotherapies, reflecting its robust pharmaceutical and biotechnology sectors.

Europe's lung cancer market is characterized by comprehensive healthcare systems and substantial government support for healthcare research. The region has strict tobacco control policies contributing to prevention efforts. There's a strong focus on integrating advanced diagnostics, including molecular biomarker testing, to guide targeted treatment approaches. Additionally, Europe is a hub for clinical trials, aiming to develop and approve innovative therapies.

The lung cancer market in the Asia Pacific region is rapidly growing, driven by increasing healthcare expenditure and a rising incidence of lung cancer. The market is diverse, with countries at various stages of healthcare infrastructure development. There's a growing emphasis on improving healthcare facilities, increasing public awareness about cancer prevention and early detection, and adopting modern treatment modalities. Countries like Japan and South Korea are leading in technological adoption, while others are progressively enhancing their healthcare systems to provide better cancer care.

Global Lung Cancer Screening Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • Canon Medical Systems
  • Eon Health
  • Fujifilm Holdings Corporation
  • Koninklijke Philips N.V.
  • Medtronic Plc
  • Microsoft Corporation (Nuance Communications, Inc)
  • Penrad Technologies Inc.
  • Miltenyi Biotech
  • Volpara Solutions Limited.
  • General Electric


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Lung Cancer Screening Market Overview
3.1 Global Lung Cancer Screening Market Historical Value (2017-2023)
3.2 Global Lung Cancer Screening Market Forecast Value (2024-2032)
4 Global Lung Cancer Screening Market Landscape
4.1 Global Lung Cancer Screening: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Lung Cancer Screening: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Lung Cancer Screening Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Lung Cancer Screening Market Segmentation
6.1 Global Lung Cancer Screening Market by Type
6.1.1 Market Overview
6.1.2 Low Dose Computed Tomography (LDCT)
6.1.3 X-ray
6.2 Global Lung Cancer Screening Market by Age group
6.2.1 Market Overview
6.2.2 50 and older
6.2.3 Below 50
6.3 Global Lung Cancer Screening Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Diagnostic Centers
6.3.4 Others
6.4 Global Lung Cancer Screening Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Lung Cancer Screening Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Lung Cancer Screening Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Lung Cancer Screening Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Lung Cancer Screening Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Lung Cancer Screening Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Canon Medical Systems
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Eon Health
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Fujifilm Holdings Corporation
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Koninklijke Philips N.V.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Medtronic Plc
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Microsoft Corporation (Nuance Communications, Inc)
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Penrad Technologies Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 `Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Miltenyi Biotec
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Volpara Solutions Limited.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 General Electric
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Canon Medical Systems
  • Eon Health
  • Fujifilm Holdings Corporation
  • Koninklijke Philips N.V.
  • Medtronic Plc
  • Microsoft Corporation (Nuance Communications Inc)
  • Penrad Technologies Inc.
  • Miltenyi Biotec
  • Volpara Solutions Limited.
  • General Electric

Methodology

Loading
LOADING...

Table Information